Physician profile
Ashley Bevins
NPI 1275726069
$10,987.50
in general payments reported to CMS, 2019-2025
43 companies · $2,639 in 2025
The $2,639 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $1,065 · 2021: $1,105 · 2022: $1,028 · 2023: $1,506 · 2024: $2,530 · 2025: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,674.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,662.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,233.91 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $886.35 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $865.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $795.07 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $649.30 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $567.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.24 | 2020-2025 | Xifaxan |
| Pfizer INC. | $396.31 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $381.18 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $325.35 | 2019-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $320.02 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $301.97 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $222.26 | 2019-2025 | |
| Astellas Pharma US INC | $185.89 | 2019-2024 | Veozah |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bevins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.